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Clinical PerspectiveWhat Is New?Arterial closure devices reduce bedrest after cardiac procedures, but there are conflicting data on their association with major bleeding.A propensity‐matched cohort demonstrated a reduction in major bleeding among patients who received a closure device, but also a numerical decrease in the falsification end point of contrast‐induced nephropathy.An instrumental variable analysis demonstrated no difference in major bleeding.What Are the Clinical Implications?These findings have implications for the use of closure devices, as well as the performance and interpretation of comparative effectiveness research in observational data sets.

Introduction {#jah34861-sec-0008}
============

Vascular complications associated with catheterization have been shown to lead to significant morbidity and mortality.[1](#jah34861-bib-0001){ref-type="ref"}, [2](#jah34861-bib-0002){ref-type="ref"}, [3](#jah34861-bib-0003){ref-type="ref"}, [4](#jah34861-bib-0004){ref-type="ref"} Compared with the femoral approach, radial arterial access has been suggested as a safer alternative to reduce the risk of adverse events with percutaneous procedures.[5](#jah34861-bib-0005){ref-type="ref"}, [6](#jah34861-bib-0006){ref-type="ref"} However, radial access is not consistently feasible for several peripheral and structural interventions. Furthermore, many operators continue to use the femoral approach because of increased familiarity with the procedure. Prior research has demonstrated that these considerations contribute to the persistent overwhelming use of the femoral approach for invasive coronary procedures in the United States.[7](#jah34861-bib-0007){ref-type="ref"}

Arterial closure devices (ACDs) are one strategy that has been proposed to decrease vascular complications after femoral catheterization.[8](#jah34861-bib-0008){ref-type="ref"} Prior research has suggested that the use of these devices is associated with a reduction in major bleeding, although the data on clinical outcomes have been inconsistent because of methodological limitations.[9](#jah34861-bib-0009){ref-type="ref"}, [10](#jah34861-bib-0010){ref-type="ref"}, [11](#jah34861-bib-0011){ref-type="ref"} More specifically, comparative effectiveness analyses of closure devices compared with manual compression for arterial hemostasis are often plagued by residual confounding.[8](#jah34861-bib-0008){ref-type="ref"} The specifics of vascular anatomical characteristics at the puncture site (eg, the preponderance of atherosclerotic plaque) are rarely available, making it challenging to incorporate characteristics associated with bleeding complications into risk adjustment models. Because of this, there are no professional society guidelines available for the use of closure devices, and conventional practices have been drawn from consensus opinion. Furthermore, there has not been a contemporary analysis of closure device use in a large cohort of patients to assess the present state of use and efficacy with the advent and increased use of transradial techniques.

Accordingly, we leveraged clinical and procedural data from the Veterans Affairs (VA) Clinical Assessment, Reporting, and Tracking Program to define the temporal trends and clinical outcomes associated with closure device use among patients undergoing percutaneous coronary intervention within the largest integrated healthcare system in the United States, the VA Healthcare System.

Methods {#jah34861-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request, although will be subject to the stringent data privacy rules of the VA Healthcare System and the US government.

Population {#jah34861-sec-0010}
----------

The VA Clinical Assessment, Reporting, and Tracking Program is a national quality and safety oversight organization for invasive cardiac procedures performed by cardiologists throughout the VA Healthcare System. As described previously, this program captures and compiles standardized patient and procedural data elements for all coronary procedures performed in VA cardiac catheterization laboratories.[12](#jah34861-bib-0012){ref-type="ref"} The data elements surveyed are derived from previously established data definitions from the National Cardiovascular Data Registry.[13](#jah34861-bib-0013){ref-type="ref"} The present analysis includes patients who underwent percutaneous coronary intervention through a single femoral access site within this healthcare system between December 1, 2004, and September 30, 2018. Patients who underwent emergent procedures or those who required mechanical support (intra‐aortic balloon pump/Impella) and thus larger‐bore access were excluded from the analysis. In addition, interventions performed by an operator who had performed \<20 cases were excluded. This cohort was used to define temporal trends and variability in closure device use. The analytic cohort was further refined for the assessment of clinical outcomes. For patients who underwent multiple interventions during the study period, one procedure for each patient was randomly chosen for inclusion in the analysis. Patients were excluded for multiple access points during a single procedure, and for missing key data points, such as complete periprocedural (before and after) hemoglobin levels. This study was approved by the Colorado Multiple Institutional Review Board, which includes the Rocky Mountain Regional VA Medical Center, with a waiver of informed consent.

Definitions {#jah34861-sec-0011}
-----------

The mechanism of femoral artery hemostasis was derived from clinical documentation from the operator performing the procedure. Documentation of a *suture*,*collagen plug*, or *clip* to close the femoral artery was defined as cases that used a closure device. Alternatively, documentation of *manual* hemostasis to close the femoral artery was defined as cases that did not use a closure device. Cases using *other* closure methods or those that did not have a closure method documented were necessarily excluded.

Measurements and Outcomes {#jah34861-sec-0012}
-------------------------

Patient and procedural information was derived from the electronic medical record and cardiac catheterization report documentation. The primary outcome was the occurrence of bleeding, defined as a decline in postprocedure hemoglobin by at least 3 g/dL compared with preprocedure values or the administration of a blood transfusion within 2 days of the coronary intervention. These values approximate Bleeding Academic Research Consortium 3a criteria.[14](#jah34861-bib-0014){ref-type="ref"} The occurrence of contrast‐induced nephropathy was also assessed as a secondary falsification end point. This was defined as an absolute increase of serum creatinine of ≥0.3 mg/dL or a relative increase of 50% in serum creatinine within 72 hours of coronary intervention.

Statistical Analysis {#jah34861-sec-0013}
--------------------

The temporal trends and variation in the use of closure devices across facilities and operators were performed using standard descriptive statistics. Baseline patient and procedural characteristics were compared among patients who received a closure device and those who received manual hemostasis. Continuous variables were presented as means and SDs, whereas categorical variables are reported as counts and percentages. Standardized differences were provided for comparisons independent of sample size.

### Propensity score {#jah34861-sec-0014}

A propensity score was estimated on the basis of the conditional probability that a closure device would be used, including covariates accounting for patient characteristics (age/sex/body mass index), medical comorbidities (cerebrovascular disease/chronic kidney disease/chronic obstructive lung disease/hypertension/hyperlipidemia/prior percutaneous intervention), medical presentation (acute coronary syndromes), and facility characteristics (training facility) as well as the time of the procedure. Additional covariates for concomitant medication use (IIb/IIIa) were also included. Patients were matched using a caliper width of 0.05 SDs of the logit of the propensity score, and preferentially matched to others within their same facility. Standardized differences \<10% were considered to indicate adequate balance across groups.[15](#jah34861-bib-0015){ref-type="ref"} Finally, a model was constructed using our matched cohort to estimate the adjusted risk difference for the effect of a closure device on bleeding. All analyses were performed using R, version 3.4.1, with matching preformed with the Matching package.

### Instrumental variable {#jah34861-sec-0015}

As the decision to use a closure device has the potential to be influenced by unmeasured confounding, an instrumental variable approach was chosen as an alternative method to estimate the effectiveness of closure device use. The instrumental variable used in this analysis was the variation in closure device use by operator, quantified as the proportion of cases in which a closure device was used in the prior 20 interventions. This preference‐based instrumental variable measures the operator proclivity for using a closure device.[16](#jah34861-bib-0016){ref-type="ref"} To further strengthen the instrumental variable, a binary instrument was defined as being performed by a high‐ versus low‐ACD use preferring operator. Specifically, the intervention was identified as being done by a high‐ACD use operator if the ratio of percutaneous coronary interventions with ACD use in the prior 20 percutaneous coronary interventions for the operator was in the top quartile of proportion of ACD use and by a low‐ACD use operator if the ratio was in the bottom quartile.

The 2‐stage least squares linear regression method was used to perform the instrumental variable analysis to estimate the effect of closure devices on our primary outcome and falsification end point. This method includes 2 sequential linear regression models where in the first‐stage model we regressed ACD status on our instrument while also adjusting for all patient, procedural, and facility characteristics as well as fiscal year quarter. The second‐stage model included the regression of our binary outcome on the predicted value of receiving a closure device as estimated from the first‐stage model with adjustment for listed covariates. Huber‐White cluster robust SEs were estimated for the second‐stage model to account for heteroscedasticity, for sampling error in the first‐stage estimate, and for clustering of patients within site. The coefficient of the predicted value of receiving a closure device in the second‐stage model gave us our estimated effect of interest of the adjusted risk difference in site bleeding with closure device use in the subpopulation of compliers, those who would receive a closure device only if they went to high‐use operators. All analyses were performed using R, version 3.4.1, with the 2‐stage least squares linear regression method executed with the package AER and cluster robust SEs calculated with the package ivpack. *P*\<0.05 was considered statistically significant.

Results {#jah34861-sec-0016}
=======

During the time period under investigation, 132 373 coronary interventions were performed by 681 operators. Emergent cases requiring mechanical support (n=1090) or a salvage intervention (n=79) were excluded. Similarly, cases that were not performed via the femoral approach (n=30 892) or used *other* or unidentified closure methods (n=13 196) were also removed from the base cohort. Finally, cases where an operator was not listed (n=1385) were removed, leaving 85 731 interventions available to analyze temporal trends and site variation. The cohort was further refined for the analysis of clinical outcomes, with 3519 cases excluded for multiple access sites and 24 936 excluded for missing data necessary to assess risk of bleeding or bleeding outcomes, such as body mass index or periprocedural hemoglobin. The final analytic cohort subsequently consisted of 40 718 interventions performed on unique patients by 323 different operators (Figure [1](#jah34861-fig-0001){ref-type="fig"}).

![Diagram of cohort construction.](JAH3-9-e015223-g001){#jah34861-fig-0001}

Temporal Trends {#jah34861-sec-0017}
---------------

The temporal trends in closure device use among patients undergoing coronary intervention via the femoral approach are demonstrated in Figure [2](#jah34861-fig-0002){ref-type="fig"}. As shown, the proportion of cases that used a mechanical closure device increased from 60.4% in fiscal year 2006 to 75.3% in fiscal year 2018, consistent with an average increase of 1.2% each year (linear trend *P*\<0.0001).

![Temporal trends in the use of arterial closure devices (ACDs). The proportion of cases that used a mechanical closure device increased from 60.4% in fiscal year 2006 to 75.3% in fiscal year 2018, consistent with an average increase of 1.2% each year (linear trend *P*\<0.0001). Q indicates quarter.](JAH3-9-e015223-g002){#jah34861-fig-0002}

Operator and Site Variation {#jah34861-sec-0018}
---------------------------

There was significant variation in the use of closure devices dependent on both operator and site. The proportion of closure device use for operators ranged from 0% to 100%, with a median of 72.1% (interquartile range, 44.9%--88.8%). Similarly, sites varied in the proportion of closure device use, with a range of 0% to 100% and a median of 73.1% (interquartile range, 52.9%--87.1%).

Clinical Outcomes {#jah34861-sec-0019}
-----------------

The characteristics of the patients in analytic cohort for clinical outcomes are presented in Table [1](#jah34861-tbl-0001){ref-type="table"}, stratified by the use of a closure device. Most notably, patients who received a closure device had significantly lower rates of peripheral artery disease (19.8% versus 26.1%; Absolute Standardized Difference \[ASD\], 19.8) and prior bypass surgery (29.3% versus 34.4%; ASD, 10.8) compared with those who did not. Fewer patients treated with a closure device were also treated with concomitant IIb/IIIa inhibitors (13.1% versus 17.4%; ASD, 12.0).

###### 

Patient Characteristics

  Characteristic                                 Overall (n=40 718)   ACD (n=27 505)   No ACD (n=13 213)   Standardized Difference, %
  ---------------------------------------------- -------------------- ---------------- ------------------- ----------------------------
  Closure device type                                                                                      
  Manual                                         13 213 (32.5)        ...              13 213 (100.0)      ...
  Collagen plug                                  504 (1.2)            504 (1.8)        ...                 ...
  Extravascular plug                             2 (0.0)              2 (0.0)          ...                 ...
  Seal                                           18 489 (45.4)        18 489 (67.2)    ...                 ...
  StarClose/clip                                 1072 (2.6)           1072 (3.9)       ...                 ...
  Suture                                         7438 (18.3)          7438 (27.0)      ...                 ...
  Demographics                                                                                             
  Age, mean (SD), y                              66.4 (9.4)           66.3 (9.4)       66.7 (9.3)          5.1
  Men                                            39 975 (98.2)        27 025 (98.3)    12 950 (98.0)       1.8
  White                                          34 116 (83.8)        22 967 (83.5)    11 149 (84.4)       2.4
  BMI, mean (SD), kg/m^2^                        30.2 (5.7)           30.3 (5.6)       29.9 (5.8)          7.2
  Tobacco use                                    25 694 (63.1)        17 124 (62.3)    8570 (64.9)         5.4
  Hypertension                                   37 026 (90.9)        24 868 (90.4)    12 158 (92.0)       5.7
  Hyperlipidemia                                 36 805 (90.4)        24 871 (90.4)    11 934 (90.3)       0.4
  Renal failure (GFR \<30 ml/min/1.73 m^2^)      2066 (5.1)           1265 (4.6)       801 (6.1)           6.5
  Chronic kidney disease                         9831 (24.1)          6409 (23.3)      3422 (25.9)         6.0
  Cerebrovascular disease                        7811 (19.2)          5035 (18.3)      2776 (21.0)         6.8
  Peripheral arterial disease                    9166 (22.5)          5439 (19.8)      3727 (28.2)         19.8
  Obstructive lung disease                       9648 (23.7)          6201 (22.5)      3447 (26.1)         8.3
  Diabetes mellitus                              20 486 (50.3)        13 700 (49.8)    6786 (51.4)         3.1
  Congestive heart failure                       11 755 (28.9)        7594 (27.6)      4161 (31.5)         8.5
  Chronic depression                             12 439 (30.5)        8378 (30.5)      4061 (30.7)         0.6
  Posttraumatic stress                           6690 (16.4)          4564 (16.6)      2126 (16.1)         1.4
  Prior myocardial infarction                    17 496 (43.0)        11 586 (42.1)    5910 (44.7)         5.3
  Prior PCI                                      18 326 (45.0)        12 301 (44.7)    6025 (45.6)         1.8
  Prior CABG                                     12 613 (31.0)        8072 (29.3)      4541 (34.4)         10.8
  Presentation characteristics                                                                             
  Medication IIb/IIIa                            5891 (14.5)          3596 (13.1)      2295 (17.4)         12.0
  Outpatient PCI                                 217 (0.5)            149 (0.5)        68 (0.5)            0.4
  Presentation type                                                                                        
  STEMI                                          2855 (7.0)           1909 (6.9)       946 (7.2)           3.4
  NSTEMI                                         9786 (24.0)          6647 (24.2)      3139 (23.8)         
  Unstable angina                                9995 (24.5)          6778 (24.6)      3217 (24.3)         
  Stable angina                                  11 681 (28.7)        7927 (28.8)      3754 (28.4)         
  Chest pain                                     1705 (4.2)           1135 (4.1)       570 (4.3)           
  Other[a](#jah34861-note-0003){ref-type="fn"}   778 (1.9)            530 (1.9)        248 (1.9)           
  Unknown                                        3527 (8.7)           2335 (8.5)       1192 (9.0)          

Data are presented as counts (proportions) unless otherwise noted.

ACD indicates arterial closure device; BMI, body mass index; CABG, coronary artery bypass grafting; GFR, glomerular filtration rate; NSTEMI, non--ST‐segment--elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.

Other: presentations for valve diseases, arrhythmia, asymptomatic, cardiomyopathy, heart failure, positive functional study, noncardiac preoperation, pulmonary hypertension, syncope, and transplant evaluation.

### Propensity matching {#jah34861-sec-0020}

The association of closure device use and bleeding was first assessed using propensity matching. Using this approach, 26 336 (65%) patients were included in the matched analysis, with inclusion of 13 168 patients who did not receive a closure device (99.6% of the manual device cohort). A summary of the unmatched and matched cohorts, stratified by propensity score, is depicted in Figure [S1](#jah34861-sup-0001){ref-type="supplementary-material"}, demonstrating excellent overlap in the matched population. This is consistent with the clinical and procedural characteristics of in the matched cohort, with evidence of excellent balance between those who did or did not receive a closure device (Table [S1](#jah34861-sup-0001){ref-type="supplementary-material"}). The facility characteristics in the propensity‐matched cohort were also similar (Table [S2](#jah34861-sup-0001){ref-type="supplementary-material"}). After binomial regression, the estimated average treatment effect for those who received a closure device suggested a 1.1% reduction in risk (95% CI, −1.5% to −0.6%) in periprocedural bleeding. Closure devices were also associated with a reduction in the point estimate of contrast‐induced nephropathy (−0.6%; 95% CI, −1.3% to 0.1%) that did not reach statistical significance (*P*=0.10).

### Instrumental variable {#jah34861-sec-0021}

The instrumental variable used for this analysis was the proportion of 20 prior interventions that an operator performed using a closure device, divided into the upper (high‐use) and lower (low‐use) quartiles, at the time of the intervention of interest (Figure [S2](#jah34861-sup-0001){ref-type="supplementary-material"}). Using this as the instrument, Table [S3](#jah34861-sup-0001){ref-type="supplementary-material"} summarizes the difference in patient characteristics treated by high‐use and low‐use operators. This constituted a total of 20 883 (51%) patients, removing the patients in the middle quartiles to strengthen the instrumental variable. Once again, the use of a concomitant IIb/IIIa inhibitor was lower among those with a closure device compared with those without (12.9% versus 18.6%; ASD, 15.9). The facility characteristics stratified by the instrument are reproduced in Table [S4](#jah34861-sup-0001){ref-type="supplementary-material"}, demonstrating a lower proportion of academic affiliations (92.9% versus 100.0%; ASD, 39.0) and trainees (82.3% versus 98.1%; ASD, 54.9) at sites with high closure device use operators. The crude bleeding rates of patients treated by these operators are summarized in Table [S5](#jah34861-sup-0001){ref-type="supplementary-material"}, with the rates similar among high‐use operators (3.54 per 100 cases) and low‐use operators (3.58 per 100 cases). After adjustment for patient, procedural, and facility characteristics, there was no difference in bleeding rate using the instrumental variable approach, with an average treatment effect of 0.2% (95% CI, −0.9% to 1.2%). There was also no difference in the falsification end point, contrast‐induced nephropathy, between those who received a closure device and those who did not (0.5%; 95% CI, −1.4% to 2.4%).

The clinical outcomes stratified by analytic method are reproduced in Table [2](#jah34861-tbl-0002){ref-type="table"}. As shown, unadjusted regression (*P*=0.004) and propensity‐matched analyses (*P*\<0.001) suggest that closure devices are associated with a reduction in periprocedural bleeding. However, adjusted regression (*P*=0.08) and an instrumental variable analysis (*P*=0.74) designed to address residual confounding did not demonstrate the same relationship.

###### 

Risk Difference Estimates for the Association Between Closure Device and Bleeding Using Different Methods

  Model                   Adjusted Risk Difference (95% CI)   *P* Value
  ----------------------- ----------------------------------- -----------
  Unadjusted regression   −0.00754 (−0.0127 to −0.00241)      0.004
  Adjusted regression     −0.00473 (−0.0100 to 0.000574)      0.08
  Instrumental variable   0.00178 (−0.00887 to 0.0124)        0.74
  Propensity score        −0.0106 (−0.0152 to −0.00611)       \<0.0001

Discussion {#jah34861-sec-0022}
==========

The present study evaluated the temporal trends and clinical outcomes associated with the use of ACDs after coronary revascularization. As the data demonstrate, the use of closure devices has significantly increased over the past decade, albeit with significant variation across different medical centers. A propensity‐matched analysis demonstrates that use of these devices is associated with a reduction in major bleeding. However, these devices were also associated with a trend toward a reduction in contrast‐induced nephropathy in the same matched cohort, suggesting the possibility of residual confounding. With this in mind, an instrumental variable analysis was performed that demonstrated similar major bleeding risk between patients who did and did not receive closure devices. These data have implications both for the use of closure devices during invasive cardiac procedures, but also for the performance and interpretation of comparative effectiveness research using observational data sets.

The use of femoral ACDs has increased over time with site‐level variation. A survey of international interventional cardiologists has suggested that vascular closure devices are used in \>40% of coronary angiograms and interventions performed via the femoral approach.[17](#jah34861-bib-0017){ref-type="ref"} This is consistent with data derived from large registries in the United States, where \>50% of patients undergoing coronary intervention via the femoral approach received an ACD.[8](#jah34861-bib-0008){ref-type="ref"} In the present analysis, we demonstrate that closure device use in the Veterans Health Administration is increasing by \>1% each year, such that 75% of coronary interventions performed via femoral approach were closed with a device in the most recent year analyzed. Increased use of closure devices likely reflects the decreased bedrest required once these devices are used, significantly increasing patient comfort. Multiple prior analyses have also demonstrated that these devices are cost‐effective as they facilitate earlier patient ambulation and potential discharge.[18](#jah34861-bib-0018){ref-type="ref"}, [19](#jah34861-bib-0019){ref-type="ref"} Our data do demonstrate significant operator and site‐level variation in closure device use, perhaps related to the experience each site has had with these products. A further evaluation of the clinical risks associated with closure device use is thus warranted.

The association between ACDs and clinical outcomes has been inconsistent, largely because of methodologic limitations in observational analyses. Previous research demonstrated that the use of closure devices may be associated with a reduction in vascular complications when compared with manual compression.[20](#jah34861-bib-0020){ref-type="ref"}, [21](#jah34861-bib-0021){ref-type="ref"} Further studies suggested that ACDs may be associated with a reduction in short‐term mortality among propensity‐matched patients.[10](#jah34861-bib-0010){ref-type="ref"} The positive association between closure devices and clinical outcomes was also demonstrated in the present propensity‐matched analysis, which suggested a modest 1.1% reduction in the risk of major bleeding with the use of a closure device. However, our propensity analysis also demonstrated that closure devices may be associated with a reduction in the point estimate for contrast‐induced nephropathy. The concomitant reduction in this falsification end point suggests potential differences in the underlying patient population that could not be accounted for during propensity matching, and it is consistent with the known variation in the use of closure devices on the basis of poorly captured patient characteristics. Conversely, when analyzed with an instrumental variable approach, similar bleeding rates were demonstrated between those who received a closure device and those who did not. Instrumental variable analyses are specifically designed with the intent of isolating a treatment effect, independent of unmeasured variation. An instrumental variable (operator preference for use of closure devices in the present analysis) is associated with the exposure (closure device use) but not with the outcome (bleeding), except through its association with the exposure. Thus, by using a method to compare cases where an operator chooses whether to use a closure device independent of patient factors, one can minimize the impact of unmeasured patient factors that may influence the outcome. Interestingly, this is consistent with the results from a large randomized clinical trial demonstrating that vascular closure devices were noninferior to manual compression among patients undergoing coronary angiography.[22](#jah34861-bib-0022){ref-type="ref"}

The present analyses demonstrate the potential limitations of comparative effectiveness analyses using observational data sets. A strong association between closure devices and major bleeding was established using unadjusted regression and propensity‐matched methods, with a nonsignificant trend also demonstrated with adjusted regression. Each of these methods has been used to evaluate this association previously, often with positive findings.[10](#jah34861-bib-0010){ref-type="ref"}, [20](#jah34861-bib-0020){ref-type="ref"}, [21](#jah34861-bib-0021){ref-type="ref"} Some have questioned the use of these methods because of the significant risk of residual confounding by factors that could not be identified or incorporated into the regression or propensity models.[23](#jah34861-bib-0023){ref-type="ref"} These *unknown unknowns* can lead to erroneous conclusions about the association between a predictor and an outcome, potentially influencing clinical practice in a wide range of disciplines. A large observational study comparing percutaneous and surgical revascularization using a propensity‐matched cohort, for example, demonstrated superior outcomes with surgery.[24](#jah34861-bib-0024){ref-type="ref"} The authors recognized the potential role of unknown confounders, however, and constructed a sensitivity analysis demonstrating that the results would be questioned if 20% of the cohort had an unmeasured characteristic that increased the risk of percutaneous revascularization by \>3‐fold. A confounder with these characteristics, surgical ineligibility, was later identified in these proportions with this effect size in another data set.[25](#jah34861-bib-0025){ref-type="ref"} In the present analysis, propensity methods suggested an association between closure device use and reductions in bleeding. However, a similar association between closure device use and the falsification end point of contrast nephropathy raises concern that residual confounding is present, wherein patients not receiving closure devices may be selected against because of factors that may associate with increased bleeding, like peripheral vascular disease. Alternative analytic methods can be used to address the residual confounding that plagues observational analyses, including falsification end points and instrumental variable analyses. These analytic tools were valuable in identifying potential residual confounding among patients receiving closure devices and should be considered when performing other comparative effectiveness analyses using observational data sets in the future.

Limitations {#jah34861-sec-0023}
-----------

The present project should be interpreted in the context of several limitations. Similar to prior studies, the current analysis is derived from data reported by the clinicians providing clinical care. Incomplete or incorrect data entry is possible, although steps have been taken to validate and adjudicate the recorded information. As referenced, unmeasured confounding can be present in observational analyses. We have used multiple different analytic methods to assess for residual confounding when formulating our conclusions. Heterogeneous results produced by these methods could reflect residual confounding, but may also be valid representations of the effect of a therapy in different subpopulations as the instrumental variable cohort was distinct from the cohort used for propensity matching. In addition, clinical outcomes were derived from laboratory data or the administration of blood products. The data set does not allow us to easily discriminate between access or nonaccess site bleeding, such that it is possible that some episodes of major bleeding were unrelated to the use of closure devices. Alternative end points, such as limb ischemia or arterial dissection, were not frequently reported and thus could not be included in the analysis. Use of a closure device was assumed to be successful, and it is possible that some bleeding events were related to unsuccessful deployment or device failure in the hands of inexperienced operators and not attributable to appropriate device use. Furthermore, we analyzed all closure devices as a group, and it is likely that some closure devices have greater efficacy than others.[26](#jah34861-bib-0026){ref-type="ref"} An analysis of the differences in efficacy was not entertained because of the concerns about residual confounding that were highlighted in the primary analysis. Finally, the VA patient population is unique and may not be representative of a broader national population that includes a higher proportion of women and minorities. A contemporary randomized trial could obviate some of these limitations.

Conclusions {#jah34861-sec-0024}
===========

In conclusion, the use of ACDs has increased over time, with significant site variation. ACDs are associated with a reduction in major bleeding within a propensity‐matched cohort, which dissipates in an instrumental variable analysis. These data highlight some of the methodologic limitations of comparative effectiveness research in observational analyses.
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**Table S1.** Baseline clinical and procedural characteristics stratified by closure device in a propensity matched cohort.
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**Table S3.** Baseline clinical and procedural characteristics by high and low use of closure devices.
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**Figure S2.** Histogram of proportion of providers previous twenty cases that utilized a closure device.

###### 

Click here for additional data file.

This material is the result of work supported with resources and use of facilities at the Rocky Mountain Regional VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.
